New Clinical Research trends in Oncology

A symposium on trends in Clinical Oncology was recently held in Madrid, Spain. The symposium gathered actors from the private health system (Hospital Madrid – Clara Campal, Onkologikoa, Clínica Universidad de Navarra), as well as pharmaceutical companies (Roche, Novartis).

The interest of this symposium is that it had a look at the research on cancer from the perspective of clinicians coming from private hospitals, and not from the National Health Systems. [Read more…]

New biomarkers in periodontal disease

Periodontitis, also generally called gum disease or periodontal disease, begins with bacterial growth in the mouth and may end, if not properly treated, with tooth loss due to destruction of the tissue that surrounds your teeth. It’s not only an issue of aesthetics, it’s also an issue of health, as it might affect nutrient intake and digestion, affecting quality of life.

To make it simple, depending on the seriousness of the disease, we talk about either gingivitis (gum inflammation), that usually precedes periodontitis (gum disease). Not all gingivitis progresses to periodontitis. [Read more…]

Diluting samples for proteomics – biomarker profiling case studies (I)

To dilute or not to dilute biological samples? And if yes, how much? That’s the question!

Following our post on whether samples should be pooled or not when performing studies for Biomarker discovery, it’s now time to discuss sample dilution (yes or no) and dilution factor (how much) when performing proteomic analysis of Biomarkers. [Read more…]

Exosomes and neuroinflammation

Following our series of posts on the role of exosomes in cancer (TME, signaling), let’s have a look at Neurobiology today. Because exosomes are everywhere (even in beer!).


Composition of exosomes (taken from Ref. 1).

Years ago, exosomes were considered as ‘extracellular debris’, but in fact they are mediators of intercellular communication by delivering functional proteins, mRNA transcripts and miRNA to recipient cells. In Neurobiology, it has been suggested that they primarily serve as signaling organelles which also remove unwanted cellular components in the brain. However, accumulating evidence suggests that exosomes can also contribute, significantly, to the development of several neuropathologies. [Read more…]

Direct access to Biomarker Profiling identification tools

Profiling tools have an increasing interest for identifying new biomarkers. Different tools are available, from classical gene profiling on DNA chips, RT-qPCR arrays, Protein arrays for secretome or transcriptome, mRNA arrays and finally miRNA arrays. All these techniques sometimes require specific material for reading arrays, and some bioanalytics to extract valuable markers of interest.

Expand your knowledge – a new visionArrays - Blog Thumbnail

The increasing focus on these tools is obvious as they help to expand scientific knowledge on sometimes well-known pathways. Why restrict your analysis to classical markers instead of checking the impact on more than 100 biomarkers… at a similar cost? Value of results is obvious as well, as it offers a convenient way to identify original pathways.

The “Start smart” attitude

Facing a new project is always a stressful situation. Biomarkers chosen are generally based on literature, which may lead to duplicating, more or less, already existing information. Searching for innovative pathways looks more like a cherry-picking, highly risky strategy. At the end, this may lead to rather conservative conclusions. A striking example concerns Western blots (WB) which everybody knows may be time consuming, rather expensive and for sure limited in number for a given project. Nobody will ever make the decision to perform more than 100 WB to explore all the potential targets available. Lab’s budgets can’t survive such a strategy, and probably the time allocated to a project cannot suffer such delays…

Protein profiling on secretome or transcriptome now allows you to study more than 1000  targets from a single sample at once. Pricing is equivalent to 10 to 20 WB traditional WB. Results obtained are of top value as they immediately orientate research focus to appropriate pathways without having the risk of missing crucial information. This helps to speed up projects, focus research towards original biomarkers and at the end deeply differentiate published results.

But not everybody has the appropriate material to perform these assays, nor is used to handling these arrays. This generally needs adapted scanners to perform readouts and once results are obtained, spots need to be further analyzed to guarantee final quality. It requires some skill. One can understand the reluctance to jump into these technologies when they are only of occasional need.

So where’s the solution?

For these reasons, tebu-bio has developed over these last years a complete Profiling – Biomarker identification platform that offers researchers access to various solutions. With a complete offer including RT-qPCR arrays, protein arrays for soluble or signal transduction markers, mRNA and miRNA arrays, we help researchers to immediately identify biomarkers involved in their domains. This information, which often appears as the initial step in project management, drives studies in the appropriate direction, rapidly and in a cost effective way.

The service process is extremely simple. After defining the most appropriate solution regarding goals of interest, your samples are tested and results sent back. Time frame is generally 2 to 4 weeks depending on starting material. A dedicated project manager is always available for any questions throughout the project. There is no license involved in these studies, which are performed in our own, European-based labs near Paris.

For those who don’t have access to cell culture facilities, our cell culture platform is also ready to collaborate, with access to a large stock of primary cells.

And the next step…

Well, if you’re curious to know how this could help boost your research, get in touch to see exactly how it can work! Just leave your question or comments below.

miRNA and cytokine profiling in hypoxic adipose tissue

In a recent publication, Mennesson E. et al. have developped a smart approach to perform both adipokine protein and miRNA profilings in in vitro adipocyte models mimicking the physiological state of adipose tissues. Adipokines and miRNAs are now known to be involved in adipose tissue metabolism in obesity during which hypoxic adipose tissue development is seen due to tissue mass expansion. Such Cytokine and miRNA profilings are thus needed to better decipher the physiopathology of obesity and to identify new biomarkers.

[Read more…]

MDR1 activity enhancement reduces senescence markers

During the last International Federation of Societies of Cosmetic Chemists (IFSCC) congress (Paris, Oct. 2014), Hajem N. et al (ALES Groupe) have shown that by enhancing MDR activity of fibroblasts grown in vitro, a positive effect on fibroblast cells was detected. In addition to directly testing MDR1 activity, the authors also used a genomic profiling approach to correlate the protective effect of their D-GlyOx complex with a reduction in senescence biomarkers on treated fibroblasts.

tebu-bio’s laboratories supported the Ales Groupe (LIERAC, PHYTO, CARON, Laboratoire DUCASTEL) by providing fibroblast cellular models and measuring the anti-ageing effect of their D-GlyOx complex by genomic profiling,

Source: Hajem N. et al “MultiDrug Resistance (MDR) proteins: active protective system, source of cell longevity” – International Federation of Societies of Cosmetic Chemists (IFSCC) congress – Oct. 27-30, 2014 – Paris) Poster # P-080.

How to get the most out of your biobank

For years, clinicians and researchers have gathered enormous collections of samples coming from different patients. These samples enable retrospective studies in order to better understand the mechanisms underlying a variety of diseases, helping to find novel biomarkers for early diagnosis, prognosis or evaluate the response to treatment. [Read more…]

Tips for data interpretation in profiling arrays

One of the questions we usually get in the Biomarkers team, once researchers or clinicians have done profiling arrays (e.g. for secretome and kinome), is how to interpret, biologically speaking, the obtained data.

It’s not the scope of this post to give a general overview of what has been published so far, but you can always have a look at publications using profiling arrays to see how other people have presented their results. The aim of this post is to give some general “rules” or ideas to help you analyse your data… even before you do your experiment. [Read more…]

Antibody arrays: a matter of species

Research is never easy. That’s why we either like doing it or supporting it.

That said, it’s easier for some researchers than others. If you are working on human, mouse or even rat models, you have quite a wide variety of tools available. Even if you work on zebrafish, at least, you have some validated zebra antibodies, guaranteed to work for your animal model.

What if you are working on other “exotic” animal models? Not by choice, but because they are really the relevant models for your research. Let’s take some examples. [Read more…]